Cover Image

Asciminib, a novel allosteric inhibitor of BCR‐ABL1, shows synergistic effects when used in combination with imatinib with or without drug resistance

Abstract In the treatment of chronic myeloid leukemia (CML), resistance to BCR‐ABL inhibitors makes it difficult to continue treatment and is directly related to life expectancy. Therefore, asciminib was introduced to the market as a useful drug for overcoming drug resistance. While combining molecu...

Full description

Saved in:

Bibliographic Details
Main Authors:	Naoki Okamoto (Author), Kenta Yagi (Author), Sayaka Imawaka (Author), Mayu Takaoka (Author), Fuka Aizawa (Author), Takahiro Niimura (Author), Mitsuhiro Goda (Author), Koji Miyata (Author), Kei Kawada (Author), Yuki Izawa‐Ishizawa (Author), Satoshi Sakaguchi (Author), Keisuke Ishizawa (Author)
Format:	Book
Published:	Wiley, 2024-08-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Atractylodes lancea (Thunb.) DC. [Asteraceae] rhizome-derived exosome-like nanoparticles suppress lipopolysaccharide-induced inflammation in murine microglial cells
by: Kei Kawada, et al.
Published: (2024)

Evaluation of cardiovascular toxicity of the atezolizumab and bevacizumab combination
by: Takahiro Niimura, et al.
Published: (2023)

Drug-Repositioning Approaches Based on Medical and Life Science Databases
by: Yoshito Zamami, et al.
Published: (2021)

Valproic acid treatment attenuates cisplatin‐induced kidney injury by suppressing proximal tubular cell damage
by: Toshihiko Yoshioka, et al.
Published: (2023)

Effects of 5‐HT₃ receptor antagonists on cisplatin‐induced kidney injury
by: Mitsuhiro Goda, et al.
Published: (2021)

Evaluation of the potential complication of interstitial lung disease associated with antifibrotic drugs using data from databases reporting spontaneous adverse effects
by: Hideki Nawa, et al.
Published: (2022)

Discovery of preventive drugs for cisplatin‐induced acute kidney injury using big data analysis
by: Masaya Kanda, et al.
Published: (2022)

Evaluation of Potential Complications of Interstitial Lung Disease Associated With Antiandrogens Using Data From Databases Reporting Spontaneous Adverse Effects
by: Hideki Nawa, et al.
Published: (2021)

Spectrum of BCR-ABL mutations in Azerbaijanian imatinib-resistant patients with chronic myeloid leukemia
by: Aypara Hasanova, et al.
Published: (2023)

Mechanistic Insights Into Co-Administration of Allosteric and Orthosteric Drugs to Overcome Drug-Resistance in T315I BCR-ABL1
by: Hao Zhang, et al.
Published: (2022)

Overcoming the imatinib-resistant BCR-ABL mutants with new ureidobenzothiazole chemotypes endowed with potent and broad-spectrum anticancer activity
by: Ashraf K. El-Damasy, et al.
Published: (2023)

Synthesis and identification of GZD856 as an orally bioavailable Bcr-AblT315I inhibitor overcoming acquired imatinib resistance
by: Xiaoyun Lu, et al.
Published: (2017)

Synergistic cytotoxicity from combination of imatinib and platinum-based anticancer drugs specifically in Bcr-Abl positive leukemia cells
by: Yuming Wei, et al.
Published: (2015)

Assessing the effects of interprofessional education by hospital pharmacists on pharmaceutical students using a self-evaluation scale
by: Fuka Aizawa, et al.
Published: (2024)

Distribution of common BCR-ABL fusion transcripts and their impact on treatment response in Imatinib treated CML patients: A study from India
by: Sudha Sazawal, et al.
Published: (2019)

A Novel Naphthoquinone-Coumarin Hybrid That Inhibits BCR-ABL1-STAT5 Oncogenic Pathway and Reduces Survival in Imatinib-Resistant Chronic Myelogenous Leukemia Cells
by: Patricia Martín-Rodríguez, et al.
Published: (2019)

Análise de mutações do domínio BCR-ABL quinase em pacientes com leucemia mielóide crônica refratários ao tratamento com mesilato de imatinibe
by: Laine Celestino Pinto, et al.
Published: (2020)

Rho-associated protein kinase and cyclophilin a are involved in inorganic phosphate-induced calcification signaling in vascular smooth muscle cells
by: Tatsuya Tsuda, et al.
Published: (2020)

BCR/ABL positive thrombocythemia: a diagnostic dilemma
by: Lubna Zafar, et al.
Published: (2017)

Search for Therapeutic Agents for Cardiac Arrest Using a Drug Discovery Tool and Large-Scale Medical Information Database
by: Yoshito Zamami, et al.
Published: (2019)

Status of Institutional Review Board Meetings Conducted Through Web Conference Systems in Japanese National University Hospitals During the COVID-19 Pandemic: Questionnaire Study
by: Yagi, Kenta, et al.
Published: (2020)

PPFIA1-targeting miR-181a mimic and saRNA overcome imatinib resistance in BCR-ABL1-independent chronic myeloid leukemia by suppressing leukemia stem cell regeneration
by: Rui Su, et al.
Published: (2023)

A Novel ELISA-Based Peptide Biosensor Assay for Screening ABL1 Activity in vitro: A Challenge for Precision Therapy in BCR-ABL1 and BCR-ABL1 Like Leukemias
by: Oksana Montecchini, et al.
Published: (2021)

Association between the BCR-ABL gene transcripts and the laboratory hematological profile
by: Marcelo Braga de Oliveira, et al.
Published: (2022)

Targeting BCR-ABL1-positive leukaemias: a review article
by: Steven Leak, et al.
Published: (2023)

Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India
by: Nikhil Rabade, et al.
Published: (2018)

Case Report: Specific ABL-Inhibitor Imatinib Is an Effective Targeted Agent as the First Line Therapy to Treat B-Cell Acute Lymphoblastic Leukemia With a Cryptic NUP214::ABL1 Gene Fusion
by: Egle Stukaite-Ruibiene, et al.
Published: (2022)

Frequency of BCR-ABL Gene Translocation in B-ALL Patients Associated with Clinicopathological Parameters
by: Amna Qamar, et al.
Published: (2024)

Chronic Myeloid Leukemia with Rare e1a3 BCR-ABL Transcript
by: Najia Tabassum, et al.
Published: (2024)

Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation
by: Liang Jiang, et al.
Published: (2021)

Pharmacophore mapping: Prediction of BCR-ABL kinase inhibitory activity of α-benzylthio chalcones
by: Richa Bajaj, et al.
Published: (2014)

Defining the target and the effect of imatinib on the filarial c-Abl homologue.
by: Elise M O'Connell, et al.
Published: (2017)

Pharmacokinetic drug interactions of asciminib with the sensitive cytochrome P450 probe substrates midazolam, warfarin, and repaglinide in healthy participants
by: Matthias Hoch, et al.
Published: (2022)

Sphingosine kinase 2 supports the development of BCR/ABL-independent acute lymphoblastic leukemia in mice
by: Vicki Xie, et al.
Published: (2018)

A Bcr-Abl Inhibitor GNF-2 Attenuates Inflammatory Activation of Glia and Chronic Pain
by: Gyun Jee Song, et al.
Published: (2019)

Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts
by: Michele Massimino, et al.
Published: (2021)

BCR-ABL fusion genes and laboratory findings in patients with chronic myeloid leukemia in northeast Iran
by: Hossein Ayatollahi, et al.
Published: (2018)

Fluorescence in situ hybridization patterns of BCR/ABL1 fusion in chronic myelogenous leukemia at diagnosis
by: Poonam P Jain, et al.
Published: (2012)

Pharmacokinetics of asciminib in the presence of CYP3A or P‐gp inhibitors, CYP3A inducers, and acid‐reducing agents
by: Matthias Hoch, et al.
Published: (2022)

Determination of lactate dehydrogenase (LDH) and Bcr-Abl transcript in the follow-up of patients with chronic myeloid leukemia = Determinação da lactate desidrogenase (LDH) e do transcrito Bcr-Abl em pacientes com leucemia mielóide crônica
by: Roberto Iemitsu Tatakihara, et al.
Published: (2010)